Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy.
germ cell tumors
high-dose chemotherapy
immunity
neutrophil-to-lymphocyte ratio
prognostic factor
systemic immune-inflammation index
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
04
2020
accepted:
25
06
2020
entrez:
14
9
2020
pubmed:
15
9
2020
medline:
15
9
2020
Statut:
epublish
Résumé
High-dose chemotherapy (HDCT) has curative potential in relapsed/refractory germ cell tumors (GCT). Due to the complexity of this population and the toxicity of HDCT, we evaluated the association between blood-based systemic inflammatory indexes and the outcome of GCT patients undergoing salvage treatment with HDCT in order to define additional prognostic factors able to orient clinical decision. Baseline characteristics, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and the systemic immune-inflammation index (SII) of 62 patients undergoing HDCT for GCT were retrospectively collected. The aim is to evaluate the correlation between each inflammatory marker (NLR, PLR, and SII) and response to HDCT, overall survival (OS), and progression-free survival (PFS). Using the receiver operating curve to identify the best cutoff values, it was found that patients with GCT with NLR ≥3.3 and SII ≥844,000 had shorter PFS and inferior OS. In the multivariable analysis including inflammatory markers, the International Prognostic Factor Study Group (IPFSG) risk group, age, and previous line of treatment, NLR ≥3.3 and SII ≥844,000 were identified to be independently associated with shorter PFS and OS. Moreover, NLR, PLR, and SII significantly correlate with overall response to HDCT. Associating IPFSG prognostic score to inflammatory markers at baseline of HDCT may improve prognostic information and could help physicians to make more personalized treatment decisions.
Identifiants
pubmed: 32923384
doi: 10.3389/fonc.2020.01325
pmc: PMC7457022
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1325Informations de copyright
Copyright © 2020 Cursano, Kopf, Scarpi, Menna, Casadei, Schepisi, Lolli, Altavilla, Gallà, Santini, Tonini, Chovanec, Mego and De Giorgi.
Références
J Immunother. 2015 Sep;38(7):285-91
pubmed: 26261892
Clin Breast Cancer. 2012 Aug;12(4):264-9
pubmed: 22591634
Oncotarget. 2016 Aug 23;7(34):54564-54571
pubmed: 27409344
Front Pharmacol. 2016 Oct 13;7:376
pubmed: 27790145
Cancer Cell. 2011 Nov 15;20(5):576-90
pubmed: 22094253
Eur Urol. 2006 Nov;50(5):1032-8; discussion 1038-9
pubmed: 16757095
Ann Surg Oncol. 2015 Apr;22(4):1377-84
pubmed: 25234022
Cell Physiol Biochem. 2017;44(3):967-981
pubmed: 29179180
Br J Cancer. 2005 Aug 22;93(4):412-7
pubmed: 16106248
J Clin Oncol. 2016 Feb 1;34(4):345-51
pubmed: 26460295
Ann Oncol. 2005 Jan;16(1):146-51
pubmed: 15598952
J Clin Oncol. 2005 Sep 20;23(27):6549-55
pubmed: 16170162
Int J Cancer. 1999 Dec 10;83(6):848-51
pubmed: 10597209
J Clin Oncol. 1998 Jul;16(7):2500-4
pubmed: 9667270
Br J Cancer. 2018 Mar 20;118(6):831-838
pubmed: 29485980
J Clin Oncol. 2017 Apr 1;35(10):1096-1102
pubmed: 27870561
N Engl J Med. 2014 Nov 20;371(21):2005-16
pubmed: 25409373
Cancer. 2017 Jun 15;123(12):2190-2192
pubmed: 28513824
Ann Oncol. 2008 Feb;19(2):259-64
pubmed: 18042838
Turk J Urol. 2017 Mar;43(1):55-61
pubmed: 28270952
Cancer Cell. 2013 Jul 8;24(1):130-7
pubmed: 23810565
J Clin Oncol. 2010 Nov 20;28(33):4906-11
pubmed: 20956623
Oncotarget. 2016 May 31;7(22):33210-9
pubmed: 27120807
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Br J Cancer. 2018 Mar 20;118(6):825-830
pubmed: 29485982
Bratisl Lek Listy. 2017;118(9):510-512
pubmed: 29061055
J Clin Invest. 2013 Jul 1;:
pubmed: 23863628
J Clin Oncol. 2010 Apr 1;28(10):1706-13
pubmed: 20194867